Resting Heart Rate as a Low Tech Predictor of Coronary Events in Women: Prospective Cohort Study

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.

Citation
Hsia, Judith, Joseph C Larson, Judith K Ockene, Gloria E Sarto, Matthew A Allison, Susan L Hendrix, Jennifer G Robinson, Andrea Z LaCroix, and JoAnn E Manson. 2009. Resting heart rate as a low tech predictor of coronary events in women: prospective cohort study. British Medical Journal 338: b219.

Published Version
doi://10.1136/bmj.b219

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:8000914

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Resting heart rate as a low tech predictor of coronary events in women: prospective cohort study

Judith Hsia, professor,1 Joseph C Larson, statistician,2 Judith K Ockene, professor,3 Gloria E Sarto, professor,4 Matthew A Allison, assistant professor,5 Susan L Hendrix, physician,6 Jennifer G Robinson, associate professor,7 Andrea Z LaCroix, professor,8 JoAnn E Manson, professor,8 for the Women’s Health Initiative Research Group

ABSTRACT

Objective To evaluate resting heart rate as an independent predictor of cardiovascular risk in women.

Design Prospective cohort study.

Setting The Women’s Health Initiative was undertaken at 40 research clinics in the United States.

Participants 129 135 postmenopausal women.

Main outcome measure Clinical cardiovascular events.

Results During a mean of 7.8 (SD 1.6) years of follow up, 2281 women were identified with myocardial infarction or coronary death and 1877 with stroke. We evaluated associations between resting heart rate and cardiovascular events in Cox regression models adjusted for multiple covariates. Higher resting heart rate was independently associated with coronary events (hazard ratio 1.26, 95% confidence interval 1.11 to 1.42 for highest [>76 beats per minute] v lowest quintile [62 beats per minute]; P=0.001), but not with stroke. The relation between heart rate and coronary events did not differ between white women and women from other ethnic groups (P for interaction=0.45) or between women with and without diabetes (P for interaction=0.31), but it was stronger in women aged 50-64 at baseline than in those aged 65-79 (P for interaction=0.009).

Conclusion Resting heart rate, a low tech and inexpensive measure of autonomic tone, independently predicts myocardial infarction or coronary death, but not stroke, in women.

Trial registration ClinicalTrials.gov NCT00000611.

INTRODUCTION

Resting heart rate, an indicator of autonomic nervous system tone, independently predicts coronary events in men.1-4 Evidence to date suggests that this relation is weaker or absent in women2,3,5-8 except for one study that showed a strong association of heart rate with cardiovascular death in African-American women in the National Health And Nutrition Examination Survey.9 The relation between heart rate and stroke in women is also unclear.

High sympathetic tone might serve as a marker of subclinical cardiovascular disease, or could adversely affect known risk factors such as blood pressure, glucose metabolism, and plasma lipids.3 Depression and anxiety have been associated with autonomic dysfunction10 11 and coronary events,12 but have infrequently been included in analyses of heart rate and cardiovascular risk.

We assessed resting heart rate as an independent predictor of myocardial infarction or coronary death and stroke in a large cohort of women with a broad range of cardiovascular risk, and compared the strength of these associations by age and ethnic group.

METHODS

Study population

The Women’s Health Initiative includes 161 808 postmenopausal women enrolled at 40 clinical sites into four randomised trials and an observational study from 1993 to 1998.13 The present analysis included participants from the observational study and women from the intervention and control groups in the randomised trials. We excluded women with previous myocardial infarction, stroke, or coronary revascularisation at baseline, and those reporting current use of β blockers, digoxin, or non-dihydropyridine calcium channel blockers at baseline, since these agents might affect heart rate. Accordingly the analysis included 129 133 women. The study population and collection of baseline data have been described previously.14 15

Measurement of heart rate and covariates

At baseline, women sat quietly for 5 minutes before a trained observer measured heart rate by palpating the radial pulse for 30 seconds. We selected covariates that might be expected to affect heart rate, coronary heart disease, or risk of stroke. Hypertension, smoking, consumption of caffeine and alcohol, diabetes mellitus requiring dietary or drug therapy, and high cholesterol requiring drug treatment were assessed by self-reported questionnaire at baseline. Plasma lipoproteins and glucose were not measured in most women; consequently, hypercholesterolaemia and diabetes were defined exclusively by self-report. Women brought their medications to clinic visits for inventory. Total physical activity was assessed by questions on a
frequency and duration scale for walking and other types of activity. Depression was assessed using six items from the Center for Epidemiological Studies depression scale. Anxiety was assessed by asking “Have you been a very nervous person?” with response categories “all of the time”, “most of the time”, “a good bit of the time”, “some of the time”, “a little bit of the time”, and “none of the time.” We combined the first four categories for analyses, because the first three categories encompassed less than 8% of women. Hormone use reflected blinded treatment assignment in the randomised trials and open label use of oestrogen.

Ascertainment of outcomes
Participants reported emergency room visits, overnight stays in hospital, and outpatient coronary revascularisation procedures every 6 months. Medical records for all deaths, overnight hospital stays, and outpatient coronary revascularisation procedures were scrutinised for potential outcomes of interest. Centrally trained physician adjudicators classified outcomes by reviewing medical records. Myocardial infarction was categorised using an algorithm that included symptoms, electrocardiographic findings, and cardiac enzyme measurements. Stroke was defined as rapid onset of a persistent neurological deficit not caused by trauma, tumour, infection, or other cause.

Statistical analysis
We divided resting heart rate into quintiles or deciles. For continuous markers, we evaluated differences in baseline characteristics by modelling the covariate of interest by a continuous term of heart rate category in a linear model. Categorical models were evaluated using a $\chi^2$ test comparing the marker of interest and the categories of heart rate. For multivariable analysis, we calculated hazard ratios with 95% confidence intervals from Cox regression models adjusted for all the covariates shown in the tables; age, body mass index, caffeine, and saturated fat consumption were included as continuous variables. We assessed interactions between heart rate or change in heart rate quintile and coronary heart disease or risk of stroke by age, ethnic origin, and presence of diabetes mellitus at baseline; P values were calculated from likelihood ratio tests by comparing models with and without interaction terms.

Table 1: Characteristics of study population by quintile of resting heart rate at baseline

|                          | ≤62 bpm (n=32195) | 63-66 bpm (n=23213) | 67-70 bpm (n=24235) | 71-76 bpm (n=25453) | >76 bpm (n=24039) | P value |
|--------------------------|-------------------|---------------------|--------------------|--------------------|-------------------|---------|
| Age, years               | 62.4 (7.2)        | 62.6 (7.2)          | 62.7 (7.2)         | 62.8 (7.2)         | 63.0 (7.1)        | <0.001  |
| Ethnic origin, %         |                   |                     |                    |                    |                   |         |
| White                    | 84                | 83                  | 84                 | 84                 | 83                |         |
| Black                    | 7                 | 7                   | 7                  | 8                  | 10                |         |
| Hispanic                 | 5                 | 5                   | 4                  | 4                  | 4                 |         |
| American Indian          | 0.4               | 0.4                 | 0.5                | 0.4                | 0.4               |         |
| Asian/Pacific Islander   | 3                 | 3                   | 3                  | 2                  | 2                 |         |
| Unknown                  | 1                 | 1                   | 1                  | 1                  | 1                 |         |
| Hypertension, %          | 25                | 27                  | 28                 | 31                 | 36                | <0.001  |
| Diabetes mellitus ever, %| 3                 | 3                   | 4                  | 5                  | 8                 | <0.001  |
| Current smoking, %       | 6                 | 6                   | 7                  | 8                  | 9                 | <0.001  |
| High cholesterol requiring drugs, % | 9       | 10                  | 11                 | 11                 | 12                | <0.001  |
| Depressive symptoms score, points | 2.2 (2.5) | 2.2 (2.5) | 2.3 (2.5) | 2.3 (2.6) | 2.5 (2.6) | <0.001  |
| Nervousness, %           |                   |                     |                    |                    |                   | <0.001  |
| At least some of the time| 19                | 20                  | 20                 | 20                 | 22                |         |
| A little bit of the time | 35                | 35                  | 35                 | 35                 | 35                |         |
| None of the time         | 46                | 45                  | 45                 | 44                 | 43                |         |
| Body mass index, kg/m$^2$|                   |                     |                    |                    |                   | <0.001  |
| Physical activity, metabolic equivalent-h/week | 16 (16) | 13 (14) | 13 (14) | 12 (13) | 11 (12) | <0.001  |
| Alcohol use              |                   |                     |                    |                    |                   |         |
| Current                  | 73.6              | 72.5                | 72.8               | 71.2               | 68.8              |         |
| Past                     | 15.7              | 16.4                | 16.3               | 17.6               | 19.4              |         |
| Never                    | 9.9               | 10.4                | 10.3               | 10.5               | 11.0              |         |
| Dietary caffeine, mg/day |                   |                     |                    |                    |                   | <0.001  |
| Dietary % energy from saturated fat | 10.5 (3.3) | 10.8 (3.3) | 10.9 (3.3) | 11.1 (3.3) | 11.3 (3.3) | <0.001  |
| Hormone use at baseline  |                   |                     |                    |                    |                   | <0.001  |
| None                     | 59                | 60                  | 62                 | 63                 | 66                |         |
| Unopposed oestrogen      | 23                | 21                  | 20                 | 19                 | 17                |         |
| Oestrogen with progestogen| 19               | 19                  | 18                 | 17                 | 17                |         |
| Statin use, %            | 4.7               | 5.2                 | 5.4                | 5.6                | 6.2               | <0.001  |

bpm=beats per minute. Values are mean (SD) or percentage. Diabetes mellitus ever excludes gestational diabetes.
Table 2 | Resting heart rate by quintile as a predictor of coronary events and stroke in univariable analysis

| Quintile | Myocardial infarction or coronary death | Stroke |
|----------|-----------------------------------------|--------|
| ≤60 bpm  (referent) | 1.00 | 1.00 |
| 61-66 bpm | 1.07 (0.94 to 1.23) | 1.07 (0.93 to 1.24) |
| 67-70 bpm | 1.19 (1.04 to 1.36) | 1.02 (0.88 to 1.18) |
| 71-76 bpm | 1.21 (1.06 to 1.38) | 1.21 (1.06 to 1.38) |
| >76 bpm | 1.68 (1.49 to 1.89) | 1.23 (1.07 to 1.41) |

P value <0.001, 0.07

bpm=beats per minute. Values are hazard ratio (95% CI) unless otherwise indicated. Stratified for participation in hormone trial, dietary modification trial, and observational study.

without the interaction terms. All reported P values are two-sided. Analyses were done by the statistics unit at the Fred Hutchinson Cancer Research Center using the SAS System for Windows version 9 (SAS Institute, Cary, NC).

RESULTS

During a mean of 7.8 (SD 1.6) years of follow-up, 2281 coronary events (myocardial infarction or coronary death) and 1877 strokes were identified among 129 135 postmenopausal women who at baseline did not have cardiovascular disease and were not taking bradycardiogenic drugs. Table 1 shows baseline characteristics by quintile of resting heart rate. In general, age, body mass index, and saturated fat consumption were higher and cardiovascular risk factors such as hypertension, diabetes, smoking, hypercholesterolaemia, and depressive symptoms more prevalent in women with higher resting heart rate, as was self reported nervousness. Physical activity and alcohol use were inversely related to heart rate (both P<0.001), and heart rate was lower in women who used postmenopausal hormone therapy than in those who did not (P<0.001).

In univariate analysis, resting heart rate predicted myocardial infarction or coronary death, with a hazard ratio of 1.68 (95% confidence interval 1.49 to 1.89) for the highest (>76 beats per minute) versus lowest (≤62 beats per minute) quintile (P<0.001; table 2). In multivariable analysis, higher resting heart rate was independently associated with increased coronary risk, with a hazard ratio of 1.26 (95% confidence interval 1.11 to 1.42) for the highest versus lowest quintile (P=0.001). For the highest (>80 beats per minute) versus lowest decile (≤60 beats per minute) of resting heart rate, the hazard ratio was 1.33 (95% confidence interval 1.14 to 1.55; P=0.002; data not shown).

In univariate analysis, resting heart rate also predicted stroke (table 2), with hazard ratio 1.23 (95% confidence interval 1.07 to 1.41) for the highest versus lowest quintile (P=0.007). In multivariable analysis, however, heart rate was not independently associated with stroke (P=0.64; table 3). When the multivariable analysis was limited to ischaemic stroke (n=1084), hazard ratios with 95% confidence intervals for heart rate quintiles were 1.00, 1.22 (1.00 to 1.49), 1.16 (0.96 to 1.41), 1.16 (0.96 to 1.40), and 1.24 (1.02 to 1.50), with a P value of 0.197. When the analysis was limited to haemorrhagic stroke (n=366), hazard ratios with 95% confidence intervals for heart rate quintiles were 1.00, 1.06 (0.75 to 1.49), 1.09 (0.76 to 1.56), 1.14 (0.82 to 1.59) and 0.94 (0.65 to 1.35), with a P value of 0.849.

Coronary events and stroke were independently associated with age, hypertension, diabetes, smoking, and consumption of alcohol and caffeine were associated with lower risk of coronary events, but not with stroke. Black and Asian ethnic origins were associated with lower risk of coronary events than other ethnic groups; Hispanic ethnic origin was associated with lower risk of coronary events and stroke. Use of oestrogen with progestogen was associated with a reduced risk of coronary events and stroke, compared with no oestrogen use, whereas unopposed oestrogen use was associated with a lower risk of coronary events and higher risk of stroke.

In formal interaction testing, we found that the relation between resting heart rate and coronary events or stroke did not differ between white women and those from other ethnic groups (P for interaction=0.45 for coronary events and 0.85 for stroke), and between women with and without diabetes mellitus at baseline (P for interaction=0.31 for coronary events and 0.92 for stroke). The relation with resting heart rate differed by age for coronary events (P for interaction=0.009; table 4). The association of higher heart rate with coronary events was stronger in women aged 50-64 years than in those aged 65-79 years at baseline. We noted no such interaction between heart rate and age for stroke (P for interaction=0.14).

DISCUSSION

Principal findings

In a large, diverse cohort of postmenopausal women, resting heart rate was an independent predictor of coronary events, with higher heart rate associated with greater risk. The relation between resting heart rate and risk of coronary events was stronger in younger postmenopausal women than in older ones. Resting heart rate did not independently predict stroke.

Strengths and limitations

Strengths of this analysis include the size and diversity of the cohort, the use of prospective ascertainment and adjudication of outcomes, the large number of clinical events, and the range of covariates available for analysis, including physical activity and depression. A limitation is that since electrocardiograms were not done for most of the participants, they were not used for this analysis; consequently, some women included in the analysis may have had atrial fibrillation or permanent pacemakers. We excluded individuals taking digoxin, β blockers, and calcium channel blockers, which should have covered most women with atrial fibrillation. Another limitation is that the cohort included no women younger than 50 and no men.

Relation to other studies

The association of depression with coronary heart disease has been attributed to behaviours induced by
depression, such as poor diet and physical inactivity, and its physiological consequences, including adverse effects on inflammation and on endothelial and platelet function. Depression has been associated with autonomic dysregulation, leading to increased heart rate and reduced heart rate variability. In our analysis, depressive symptoms were not associated with coronary events or stroke with or without adjustment for heart rate (data not shown), so we are unable to confirm that the relation between depressive symptoms and clinical events is mediated through autonomic effects. This limitation might be attributable to the fact that this subsample of the Women’s Health Initiative cohort had quite low scores for depressive symptoms—that is, was not very depressed.

Heart rate was higher in women with self reported nervousness than in less nervous women, but nervousness was not independently associated with either coronary events or stroke in our analysis. This finding contrasts with reports identifying anxiety as a predictor of coronary events or of poor outcome after coronary artery bypass surgery. Possible explanations are that our dataset did not include a true anxiety scale, or that adjustment for heart rate and several other variables weakened the association of coronary events with anxiety. The latter explanation might also account for the absence of an association between alcohol consumption and coronary events in the multivariable analysis.

We know from the Women’s Health Initiative randomised hormone trials that unopposed oestrogen and oestrogen with progestogen are associated with increased risk of stroke, and that oestrogen with progestogen increases coronary events.

| Resting heart rate, beats per minute | Myocardial infarction or coronary death | Stroke |
|--------------------------------------|---------------------------------------|--------|
| ≤62 (referent)                      | 1.00                                  | 1.00   |
| 63-66                                | 1.02 (0.89 to 1.17)                   | 1.04 (0.90 to 1.20) |
| 67-70                                | 1.08 (0.95 to 1.23)                   | 0.96 (0.83 to 1.11) |
| 71-76                                | 1.02 (0.89 to 1.16)                   | 1.07 (0.94 to 1.23) |
| >76                                  | 1.26 (1.11 to 1.42)                   | 1.01 (0.87 to 1.16) |

| Age, per 5 year increase             | 1.53 (1.48 to 1.58)                   | 1.69 (1.63 to 1.76) |

| Ethnic origin                        |                                       | 0.02   |
|--------------------------------------|---------------------------------------|--------|
| White (referent)                     | 1.00                                  | 1.00   |
| Black                                | 0.68 (0.57 to 0.80)                   | 1.18 (1.00 to 1.40) |
| Hispanic                             | 0.54 (0.40 to 0.74)                   | 0.71 (0.51 to 0.99) |
| American Indian/Alaskan native       | 1.11 (0.63 to 1.96)                   | 0.56 (0.21 to 1.48) |
| Asian/Pacific Islander               | 0.60 (0.43 to 0.85)                   | 0.94 (0.70 to 1.27) |
| Unknown                              | 0.91 (0.64 to 1.31)                   | 1.36 (0.98 to 1.91) |
| Hypertension                         | 1.69 (1.55 to 1.84)                   | 1.87 (1.70 to 2.06) |
| Diabetes mellitus ever               | 2.68 (2.36 to 3.03)                   | 1.94 (1.66 to 2.27) |
| Current smoking                      | 2.32 (2.03 to 2.65)                   | 1.95 (1.67 to 2.28) |
| High cholesterol requiring drugs     | 1.14 (0.98 to 1.33)                   | 1.18 (1.00 to 1.40) |
| Depression construct ≥5              | 1.08 (0.94 to 1.24)                   | 1.14 (0.98 to 1.33) |
| Nervousness                           |                                       | 0.09   |
| None of the time (referent)          | 1.00                                  | 1.00   |
| A little bit of the time              | 1.09 (0.99 to 1.20)                   | 0.96 (0.86 to 1.06) |
| At least some of the time            | 1.12 (1.00 to 1.25)                   | 1.00 (0.89 to 1.14) |
| Body mass index, per 5 kg/m² increase| 1.08 (1.04 to 1.12)                   | 1.00 (0.96 to 1.05) |
| Physical activity, per 5 metabolic equivalent-h/week increase | 0.97 (0.95 to 0.99) | 0.98 (0.97 to 1.00) |
| Alcohol use                           |                                       | 0.007  |
| Never (referent)                     | 1.00                                  | 1.00   |
| Past                                  | 1.07 (0.92 to 1.24)                   | 1.02 (0.86 to 1.20) |
| Current                              | 0.91 (0.79 to 1.04)                   | 0.92 (0.80 to 1.07) |
| Dietary caffeine, per 50 mg increase | 0.98 (0.97 to 1.00)                   | 0.99 (0.97 to 1.01) |
| Dietary saturated fat, per 5% increase| 1.13 (1.05 to 1.20)                   | 1.11 (1.03 to 1.19) |
| Hormone use at baseline               |                                       | 0.002  |
| None (referent)                      | 1.00                                  | 1.00   |
| Unopposed oestrogen                  | 0.86 (0.77 to 0.97)                   | 1.19 (1.06 to 1.34) |
| Oestrogen with progestogen           | 0.81 (0.71 to 0.94)                   | 0.85 (0.72 to 0.99) |
| Statin use                           | 1.06 (0.87 to 1.30)                   | 0.81 (0.64 to 1.03) |

Table 3 | Resting heart rate as an independent predictor of coronary events and stroke in multivariable analysis

We include the supplementation of alcohol consumption and coronary events in the multivariable analysis.
Table 4 | Interaction of resting heart rate and coronary events by age group and heart rate quintile

| Age 50-64 | Number of events (% of participants with event per year) | Hazard ratio (95% CI) |
|-----------|----------------------------------------------------------|----------------------|
| ≤62 bpm   | 163 (0.12)                                               | 1.00                 |
| 63-66 bpm | 125 (0.13)                                               | 1.02 (0.81 to 1.29)  |
| 67-70 bpm | 142 (0.14)                                               | 1.08 (0.86 to 1.35)  |
| 71-76 bpm | 147 (0.14)                                               | 1.01 (0.81 to 1.27)  |
| >76 bpm   | 222 (0.24)                                               | 1.47 (1.20 to 1.80)  |

| Age 65-79 | Number of events (% of participants with event per year) | Hazard ratio (95% CI) |
|-----------|----------------------------------------------------------|----------------------|
| ≤62 bpm   | 312 (0.37)                                               | 1.00                 |
| 63-66 bpm | 240 (0.39)                                               | 1.02 (0.86 to 1.20)  |
| 67-70 bpm | 279 (0.43)                                               | 1.08 (0.92 to 1.27)  |
| 71-76 bpm | 299 (0.43)                                               | 1.03 (0.88 to 1.21)  |
| >76 bpm   | 352 (0.54)                                               | 1.14 (0.98 to 1.33)  |

bpm=beats per minute. P for interaction=0.009; determined by comparing Cox models that included all the variables in table 1 with and without an interaction term (age*heart rate).

Nonetheless, analyses from non-randomised cohorts, including the Women’s Health Initiative observational study, have consistently shown lower cardiovascular risk in women taking hormones, for reasons that have been extensively discussed.27 28 Hormone use in the current analysis includes randomised treatment assignment in the hormone trials, as well as open label use by women not participating in those trials. Unsurprisingly, the associations with cardiovascular disease present a mixed picture.

We did not confirm the previously reported increased predictive value of resting heart rate for cardiovascular death in African-American women.9 In fact, the hazard ratio for coronary events was lower in black, Hispanic, and Asian women than in white women. Our models included 149 coronary events among black women, somewhat more than the 92 in the National Health and Nutrition Examination survey analysis. In addition to the difference in sample size, disparities between ethnic groups in identification and management of risk factors have changed since the 1970s and early 1980s when that analysis was undertaken.

We found a stronger association between increased heart rate and coronary events in women aged 50-64 than in those aged 65-79 (P for interaction=0.009). A possible explanation for this finding is that chronotropic insufficiency is more frequent in the older women, reducing the reliability of heart rate as a predictor of coronary events.

Coronary risk was consistent across the lower four quintiles of heart rate; the hazard ratio increased only in the highest quintile. This apparent threshold potentially increases the clinical usefulness of the association; individuals with heart rates in the highest quintile or decile for age could be readily identified and targeted for aggressive management of risk factors.

Conclusion
Although more elaborate, time consuming, and expensive methods are available to assess autonomic tone, we have found that simple measurement of resting pulse independently predicts coronary events, but not stroke, in postmenopausal women. The strength of this association, from lowest to highest quintile, is less than the association with cigarette smoking or diabetes mellitus, but might be large enough to be clinically meaningful, and is independent of physical activity.

Women’s Health Initiative investigators are listed at www.whi.org/ publications/WHI_investigators_shortlist.pdf.

Contributors: JH was responsible for conception and design of this analysis and drafted the manuscript. JCJ analysed and interpreted the data, JKO, GES, MAA, SLH, JGR, AZL, JEM interpreted the data and critically reviewed the manuscript. The final version was approved by all authors. JH is the guarantor.

Funding: The Women’s Health Initiative programme is funded by the National Heart, Lung and Blood Institute, National Institutes of Health, US Department of Health and Human Services through contracts N01WH22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122, 42107-26, 42129-32, and 44221. The sponsor had no role in performing this analysis or the decision to proceed to publication; representatives of the sponsor did participate in the study design.

Competing interests: None declared.

Ethical approval: The protocol and consent forms were approved by institutional review boards of the participating institutions; all trial participants provided written informed consent.

WHAT IS ALREADY KNOWN ON THIS TOPIC
Resting heart rate predicts coronary events in men
For women, the relation between heart rate and coronary events or stroke has been uncertain

WHAT THIS STUDY ADDS
Resting heart rate predicts coronary events in women
This relation is independent of physical activity and conventional risk factors
This association appears stronger in women aged 50-64 than in those aged 65 or older
Resting heart rate does not predict stroke in women
12 Todaro JF, Shen BJ, Niaura R, Spiro A 3rd, Ward KD. Effect of negative emotions on frequency of coronary heart disease (The Normative Aging Study). *Am J Cardiol* 2003;92:901-6.

13 The Women’s Health Initiative Study Group. Design of the Women’s Health Initiative Clinical Trial and Observational Study. *Control Clin Trials* 1998;19:61-109.

14 Ritenbaugh C, Patterson RE, Chlebowski RT, Caan B, Feis-Tinker L, Howard B, et al. The Women’s Health Initiative Dietary Modification Trial: overview and baseline characteristics of participants. *Ann Epidemiol* 2003;13:S87-97.

15 Stefanick ML, Cochrane BB, Hsia J, Barad DH, Liu JH, Johnson SR. The Women’s Health initiative postmenopausal hormone trials: overview and baseline characteristics of participants. *Ann Epidemiol* 2003;13:S78-86.

16 Langer RD, White E, Lewis CE, Kotchen JM, Hendrix SL, Trevisan M. The Women’s Health Initiative observational study: baseline characteristics of participants and reliability of baseline measures. *Ann Epidemiol* 2003;13:S107-21.

17 Hsia J, Wu L, Allen C, Oberman A, Lawson WE, Torrens J, et al. Physical activity and diabetes risk in postmenopausal women. *Am J Prev Med* 2005;28:19-25.

18 Wassertheil-Smoller S, Shumaker S, Ockene J, Talavera GA, Greenland P, Cochrane B, et al. Depression and cardiovascular sequelae in postmenopausal women. The Women’s Health Initiative. *Arch Intern Med* 2004;164:289-98.

19 Curb JD, McTiernan A, Heckbert SR, Kooperberg C, Stanford J, Nevitt M, et al. Outcomes ascertainment and adjudication methods in the Women’s Health Initiative. *Ann Epidemiol* 2003;13:S122-8.

20 Hendrix SL, Wassertheil-Smoller S, Johnson KC, Howard BV, Kooperberg C, Rossouw JE, et al. Effects of conjugated equine estrogen on stroke in the Woman’s Health Initiative. *Circulation* 2006;113:2425-34.

21 Kubzansky LD, Cole SR, Kawachi I, Vokonas P, Sparrow D. Shared and unique contributions of anger, anxiety and depression to coronary heart disease: a prospective study in the normative aging study. *Ann Behav Med* 2006;31:21-9.

22 Tully PJ, Baker RA, Knight JL. Anxiety and depression as risk factors for mortality after coronary artery bypass surgery. *J Psychosom Res* 2008;64:285-90.

23 Ohira T, Roux AV, Prineas RJ, Kzilbash MA, Carnethon MR, Folsom AR. Associations of psychosocial factors with heart rate and its short-term variability: multi-ethnic study of atherosclerosis. *Psychosom Med* 2008;70:141-6.

24 Kim CK, McGonay SP, Bartholomew BA, Marsh M, Dicken T, Wassertheil-Smoller S, et al. Depressive symptoms and heart rate variability in postmenopausal women. *Arch Intern Med* 2005;165:1239-44.

25 Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, et al. Effect of estrogen plus progesterin on stroke in postmenopausal women: the Women’s Health Initiative. *JAMA* 2003;289:2673-84.

26 Manson J, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, et al. Estrogen plus progesterin and risk of coronary heart disease. *N Engl J Med* 2003;349:523-34.

27 Prentice RL, Langer R, Stefanick ML, Howard BV, Pettinger M, Anderson G, et al. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women’s Health Initiative Clinical Trial. *Am J Epidemiol* 2005;162:1-11.

28 Godstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. *N Engl J Med* 2003;348:645-50.

**Accepted:** 1 November 2008